1. Market Research
  2. > Pharmaceutical Market Trends
Global Antihypertensive Drugs Market Research Report Forecast to 2023

Global Antihypertensive Drugs Market Research Report Forecast to 2023

  • March 2019
  • 124 pages
  • ID: 5770096
  • Format: PDF

Summary

Table of Contents

Search Inside


Antihypertensive Drugs Market Research Report: by Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others), by Type (Primary Hypertension, Secondary Hypertension), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others), and Region - Global Forecast till 2023

Market analysis

Antihypertensive medications are prescribed by reputed clinicians for the management of hypertension or high blood pressure. The high pervasiveness of hypertension is the essential driver of the global antihypertensive medications market. Several awareness campaigns by several government and non-profit associations are probably going to work for the market. For example, the Pulmonary Hypertension Association (PHA) offers training programs and has a solid encouraging group of people which offers patients the right information about the treatment. The rising predominance of incessant illnesses is powering the interest of antihypertensive drugs or medications. What’s more, the section of generics which has cut down patient expenses is anticipated to look good for the market over the forecast period (2018- 2023). The market is expected to grow at 2.67% CAGR during the forecast period.

Market segmentation

Based on its therapeutic classes, the global antihypertensive drugs market is segmented into beta-adrenergic blockers, calcium channel blockers, renin inhibitors, vasodilators, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, diuretics, and others. On the basis of its type, the market is bifurcated into secondary and primary hypertension. Lastly, on the basis of its distribution channels, the market is bifurcated into hospital pharmacy, e-commerce websites and online drug stores, retail pharmacy, and others.

Regional analysis

Geographically, the global antihypertensive drugs market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Merck KGaA (Germany), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), and United Therapeutics Corporation (U.S.), Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan), among others are some of the major players in the global antihypertensive drugs market.

Companies Mentioned

Merck KGaA (Germany), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), and United Therapeutics Corporation (U.S.), Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
15% Off

($4450)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Pulmonary Arterial Hypertension - Pipeline Review, H1 2019

Pulmonary Arterial Hypertension - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Pulmonary Arterial Hypertension - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, ...

2019 Pulmonary Hypertension Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

2019 Pulmonary Hypertension Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

  • $ 2199
  • February 2019

The ongoing clinical trial research report- “2019 Pulmonary Hypertension Ongoing Clinical Trials Study” analyzes the current scenario of all active Pulmonary Hypertension trials across the world. The ...

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019

  • $ 2500
  • April 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on